Alfresa Holdings heads into the final stretch of August with its lending market tightening meaningfully — borrow demand has roughly doubled since early July, even as the stock quietly extends a modest weekly gain.
The most notable development this week is the shift in how aggressively the borrow pool is being used. Availability has tightened to around 680% — still comfortable by absolute standards, but less than half the 2,640% reading seen in mid-July. That move has been steady and directional rather than volatile: each week since early July has brought a step-down in available shares relative to short interest outstanding. Borrowing costs remain low at 0.88%, though they briefly spiked to 2.09% on August 11 before retreating — a flash of demand that didn't sustain itself but bears watching. The short score has also been climbing, rising from around 37 in mid-August to 43.0 now, its highest point in the past two weeks.
The borrow tightening sits against a relatively benign price backdrop. Alfresa closed Friday at ¥2,337, up 3.9% on the week and roughly flat over the past month. Closest peer Medipal Holdings rose 3.2% on the week, while added 2.5% — suggesting the broader Japanese pharmaceutical distribution group is moving broadly in line rather than Alfresa breaking out in either direction. The stock's next earnings event is scheduled for November 9, so near-term catalysts are limited.
Institutional ownership tells a reasonably stable story. Silchester International Investors holds a dominant 14.4% stake — well clear of every other holder — and added just over two million shares as of its June filing. Vanguard, Nomura, BlackRock, and Dimensional have all made incremental additions recently, though none at a scale that changes the ownership narrative materially. The combined weight of active international managers here is notable for a mid-sized Japanese distributor, and Silchester's concentration at the top means any move from that holder would attract attention.
Valuation multiples paint a muted picture. The stock trades at 0.88x book value and 5.6x EV/EBITDA — both modest readings that reflect the low-margin, high-volume nature of pharmaceutical wholesale. A prior note from earlier in the year flagged a meaningful deterioration in factor scores, including a halved Piotroski F-score and a collapse in five-year EBIT growth expectations. The current short score of 43 ranks in the 40th percentile for the sector — neither extreme — and the analyst consensus target of ¥2,340 sits barely above the current price, implying the Street sees the stock as fairly valued rather than mispriced in either direction.
The key thing to watch is whether the gradual tightening of availability continues into September. At current pace, if borrow demand keeps building at the July-to-August rate, availability could cross below 500% — a level where the lending dynamic starts becoming more relevant to short-side positioning ahead of the November earnings date.
See the live data behind this article on ORTEX.
Open 2784 on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
